June #124 : PREP School - by Skot Hess

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Mentors-June 2006

A Growing Concern

Cover Q&A-June 2006

Supplemental Insurance

Oral Thursh Knockout

Med-Mix Warning

Chow, Babe

Tart Up Your PI

Food for Oil

Fatty Acid Trip

In the Key of Life

PREP School

PREP for the future

WAL-MART Special

Bush the Builder

The Domino Effect

Happy Birthday to Us

Can NYC Keep A Lid On AIDS?

Virgin Vaccine

Onward Christian Condoms


Raining Men

Positive Change

Growing Pains

Dolled Up

That ’80s Show

I See Dead People

Editor's Letter-June 2006

Mailbox-June 2006

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

June 2006

PREP School

by Skot Hess

Why the HIV negative take ARVs

Whether fearing broken condoms or wishing to avoid latex entirely, positive people and the negative people who love them have plenty of reason to want pre-exposure prophylaxis (PREP), a pill you could pop to prevent HIV infection, to hit shelves. Researchers started testing Viread (tenofovir) as a possible HIV blocker in 1998 and then Truvada (tenofovir and emtricitabine) in 2005. There’s no conclusive proof that either med works as PREP. But is even the possibility spurring unsafe behavior? Last summer, the Centers for Disease Control (CDC) decided to drop by gay pride events in four U.S. cities to see whether buzz about PREP had prompted sexual risk taking. Seven percent of respondents said they had taken antiretrovirals as an HIV preventive at least once.

Preliminary results from a monkey study announced in February suggest that Truvada may block HIV better than Viread, which has received the most extensive PREP testing. The CDC says even if it is approved as a preventive, PREP should not be a solo strategy. Researchers chose to test Viread and Truvada because of their relatively mild side effects, though both (as people with HIV know) can come with headaches, nausea and diarrhea. What’s more, if PREP users do get infected with HIV, they may later be resistant to the meds.

So why are people taking them as PREP? “A large number of people have not  seroconverted due to post-exposure prophylactic treatment [PEP], causing speculation about PREP,” says Jason Farrell, executive director of New York’s Positive Health Project. “And there will always be thrill seekers trying to dodge the bullet.” Says one man from Dallas who has sampled PREP, “Even if it’s not 100% effective, I think it’s a smart thing to do. It can counter the ‘stupid factor’ that often governs decision making when it comes to sex.”

Some AIDS advocates worry that researchers and funders might abandon PREP if it’s linked to condomless sex. CDC spokesperson Terry Butler thinks otherwise, adding, “[The survey results] point to the importance of current U.S. trials, which will answer questions about the impact of a daily prevention pill.” So for now, anyway, PREP’s still in session.     

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.